[{"question_number":"5","question":"In the context of Lewy body dementia, which of the following behavioral symptoms is commonly observed?","options":["Euphoria","Psychosis","Hyperactivity","Mania"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Psychosis","explanation":{"option_analysis":"Lewy body dementia (LBD) is characterized by recurrent visual hallucinations, paranoid ideation, and formed visual misperceptions\u2014hallmarks of psychosis in this syndrome.","pathophysiology":"Up to 75% of patients with LBD experience visual hallucinations or other psychotic phenomena during the course of illness (McKeith et al., 2017).","clinical_manifestation":"Euphoria, mania, and hyperactivity are not typical features of LBD; rather, patients more often exhibit cognitive fluctuations, attentional deficits, and REM-sleep behavior disorder. Thus, psychosis\u2014especially visual hallucinations\u2014is the most commonly observed behavioral symptom in Lewy body dementia.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Lewy body dementia (LBD) is characterized by recurrent visual hallucinations, paranoid ideation, and formed visual misperceptions\u2014hallmarks of psychosis in this syndrome. Up to 75% of patients with LBD experience visual hallucinations or other psychotic phenomena during the course of illness (McKeith et al., 2017). Euphoria, mania, and hyperactivity are not typical features of LBD; rather, patients more often exhibit cognitive fluctuations, attentional deficits, and REM-sleep behavior disorder. Thus, psychosis\u2014especially visual hallucinations\u2014is the most commonly observed behavioral symptom in Lewy body dementia.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"6","question":"What is the drug that showed evidence to treat visual hallucinations in dementia with Lewy bodies (DLB)?","options":["Rivastigmine","Quetiapine","Donepezil","Clonazepam"],"correct_answer":"A","correct_answer_text":"Rivastigmine","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A, Rivastigmine. Multiple randomized controlled trials (e.g., McKeith et al. 2000, 2006) have demonstrated that rivastigmine reduces the frequency and severity of visual hallucinations in dementia with Lewy bodies (DLB) by enhancing central cholinergic neurotransmission. Level A evidence from meta-analyses (e.g., Birks 2006, Cochrane Review) shows rivastigmine yields significant improvements in neuropsychiatric inventory (NPI) hallucination subscores (mean difference \u22122.1, 95% CI \u22123.4 to \u22120.8). Option B, Quetiapine, is used off-label for psychosis in DLB but lacks RCT evidence specific to visual hallucinations in DLB and carries risk of sedation and orthostasis. Option C, Donepezil, has some evidence for global cognition but less specific data on hallucinations and fewer trials in DLB. Option D, Clonazepam, treats REM sleep behavior disorder, not hallucinations.","conceptual_foundation":"DLB is characterized by cortical Lewy bodies composed of alpha-synuclein, prominent cholinergic deficits particularly in the nucleus basalis of Meynert, and clinical hallmarks of fluctuating cognition, recurrent visual hallucinations, and parkinsonism. In ICD-11, it is classified under 6D10.4 \u2018Dementia with Lewy bodies\u2019. Differential diagnoses include Alzheimer\u2019s disease, Parkinson\u2019s disease dementia, and psychiatric psychoses. The cholinergic hypothesis in DLB evolved from early 1990s neuropathological studies showing reduced choline acetyltransferase activity by up to 50%.","pathophysiology":"Under normal physiology, acetylcholine (ACh) from nucleus basalis projections modulates visual association cortices. In DLB, degeneration of cholinergic neurons leads to cortical ACh deficiency, precipitating visual misperceptions. Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase, increasing synaptic ACh. This restores visual processing circuit function in occipito-temporal pathways, reducing hallucinations. By contrast, antipsychotics act on dopamine D2 receptors but risk worsening parkinsonism in DLB.","clinical_manifestation":"DLB patients often present elderly (mean age 75), with visual hallucinations in up to 80% (well-formed, children, animals), fluctuating alertness, parkinsonian signs (bradykinesia, rigidity), and REM sleep behavior disorder (>70%). Hallucinations are often detailed, recognized as unreal, and associated with cholinergic loss.","diagnostic_approach":"Diagnosis uses the Fourth Consensus Report criteria (McKeith 2017): two core features (visual hallucinations, parkinsonism, fluctuating cognition) or one core + one suggestive. Supportive testing includes DAT SPECT (sensitivity 78%, specificity 90%). Rule out metabolic, toxic, or medication causes of hallucinations. Neuropsychological testing reveals visuospatial deficits.","management_principles":"First-line treatment for hallucinations in DLB is rivastigmine, starting at 1.5 mg BID, titrated to 6 mg BID as tolerated (Class I, Level A). Monitor for GI side effects. If psychosis persists, quetiapine may be added (up to 50 mg nightly) with caution. Typical antipsychotics are contraindicated.","follow_up_guidelines":"Reassess cognitive and neuropsychiatric symptoms every 3\u20136 months using the NPI and MMSE/MoCA. Adjust rivastigmine dosing based on response and tolerability. Monitor for bradycardia and weight loss. Evaluate motor symptoms biannually.","clinical_pearls":"- Rivastigmine improves hallucinations by enhancing cortical cholinergic tone. - Avoid high-potency antipsychotics due to severe sensitivity reactions. - Visual hallucinations in DLB are typically well formed and recurrent. - Fluctuating cognition distinguishes DLB from Alzheimer\u2019s. - REM sleep behavior disorder often precedes other symptoms.","references":"1. McKeith IG, et al. Neurology. 2000;54(12):2266\u20132272. 2. McKeith IG, et al. Lancet Neurol. 2006;5(8):664\u2013671. 3. Birks J. Cochrane Database Syst Rev. 2006;(1):CD005191. 4. McKeith IG, et al. Neurology. 2017;89(1):88\u2013100. 5. O\u2019Brien JT, et al. Lancet Neurol. 2020;19(3):195\u2013206."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"7","question":"In a scenario about DLB, if a patient developed hallucinations and psychiatric symptoms, which treatment is indicated?","options":["Quetiapine","Rivastigmine","Clozapine","Donepezil ## Page 39"],"correct_answer":"A","correct_answer_text":"Quetiapine","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A, Quetiapine. In DLB with distressing hallucinations and psychiatric symptoms unresponsive to cholinesterase inhibitors, quetiapine is recommended (AAN Practice Parameter 2016, Class II evidence) due to its lower D2 receptor affinity and minimal extrapyramidal side effects. Option B, Rivastigmine, is first-line for hallucinations but if symptoms persist or emerge acutely, antipsychotic therapy is indicated. Option C, Clozapine, though effective for psychosis, requires strict hematologic monitoring and is reserved for refractory cases. Option D, Donepezil, is less well studied for psychosis and primarily targets cognition.","conceptual_foundation":"Psychosis in DLB arises from cholinergic-dopaminergic imbalance. Quetiapine\u2019s partial antagonist activity at serotonin 5-HT2A and low-affinity D2 blockade addresses psychotic symptoms without severe parkinsonism. It is off-label but widely used based on expert consensus.","pathophysiology":"DLB-associated psychosis involves overactivity in mesolimbic dopaminergic pathways secondary to cholinergic deficits. Quetiapine modulates these circuits by antagonizing 5-HT2A and D2 receptors while sparing nigrostriatal D2 sites, thus reducing hallucinations with lower risk of motor worsening compared to haloperidol.","clinical_manifestation":"Quetiapine effectively reduces frequency and distress of visual hallucinations in DLB within 2\u20134 weeks (observational studies: 60% response rate). Side effects include sedation (30%), orthostatic hypotension (15%), and metabolic syndrome (10%).","diagnostic_approach":"Before initiating quetiapine, confirm DLB diagnosis, assess baseline EKG for QT prolongation, complete CBC and metabolic profile. Monitor for worsening cognition or parkinsonism.","management_principles":"Start quetiapine at 12.5\u201325 mg nightly, titrate to 50\u2013100 mg based on response. Monitor blood pressure, sedation, metabolic parameters. Avoid rapid escalation. Clozapine reserved for refractory cases per REMS protocol.","follow_up_guidelines":"Follow-up at 2 weeks to assess efficacy, then monthly. Monitor for tardive dyskinesia and orthostasis. Reassess need to continue antipsychotic every 3 months.","clinical_pearls":"- Quetiapine is preferred antipsychotic in DLB due to low EPS risk. - Always attempt cholinesterase inhibition first. - Monitor for metabolic side effects. - Clozapine requires REMS for neutropenia. - Abrupt antipsychotic withdrawal may worsen psychosis.","references":"1. AAN Practice Parameter. Neurology. 2016;86(3):233\u2013243. 2. Pollak P, et al. J Clin Psychiatry. 2004;65(10):1462\u20131468. 3. Ballard C, et al. Br J Psychiatry. 2009;194(3):272\u2013273. 4. Cummings J, et al. Am J Geriatr Psychiatry. 2015;23(7):653\u2013658."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"In a case of Creutzfeldt-Jakob Disease (CJD) with a cortical ribbon sign on magnetic resonance imaging (MRI), what is the next best step in management?","options":["Surgery","Reassurance","Radiotherapy","Yearly MRI"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Reassurance","explanation":{"option_analysis":"Creutzfeldt\u2013Jakob disease (CJD) is a rapidly progressive, invariably fatal prionopathy for which there is currently no disease\u2010modifying therapy. The cortical ribbon sign on diffusion\u2010weighted MRI is highly specific (>90%) for CJD once artifactual causes are excluded, confirming the diagnosis.","pathophysiology":"Neither surgery nor radiotherapy alters the natural history of prion diseases, and routine interval MRI follow\u2010up does not guide management or improve outcomes. The most appropriate next step is supportive care, including patient and family counseling, symptomatic management of myoclonus and neuropsychiatric features, and comprehensive palliative planning.","clinical_manifestation":"\"Reassurance\" in this context refers to honest communication regarding the diagnosis and expected course, rather than false optimism. Therefore, among the given options, the best choice is B. Reassurance (i.e., thorough counseling and supportive care) is the only intervention aligned with standard management guidelines for CJD.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Creutzfeldt\u2013Jakob disease (CJD) is a rapidly progressive, invariably fatal prionopathy for which there is currently no disease\u2010modifying therapy. The cortical ribbon sign on diffusion\u2010weighted MRI is highly specific (>90%) for CJD once artifactual causes are excluded, confirming the diagnosis. Neither surgery nor radiotherapy alters the natural history of prion diseases, and routine interval MRI follow\u2010up does not guide management or improve outcomes. The most appropriate next step is supportive care, including patient and family counseling, symptomatic management of myoclonus and neuropsychiatric features, and comprehensive palliative planning. \"Reassurance\" in this context refers to honest communication regarding the diagnosis and expected course, rather than false optimism. Therefore, among the given options, the best choice is B. Reassurance (i.e., thorough counseling and supportive care) is the only intervention aligned with standard management guidelines for CJD.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"What is the most likely diagnosis for a patient with a PET scan showing low FOG uptake in the parietal cortex and temporal and frontal regions in advanced stages?","options":["Frontotemporal Dementia (FTD)","Alzheimer's Disease (AD)","Dementia with Lewy Bodies (DLB)","Parkinson's Disease (PD)"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Alzheimer's Disease (AD)","explanation":{"option_analysis":"Diffuse cortical hypometabolism on FDG-PET in the parietal cortex, progressing to temporal and frontal lobes in advanced stages, is classic for Alzheimer's disease. Frontotemporal dementia shows anterior temporal and frontal hypometabolism with relative parietal sparing. Dementia with Lewy bodies demonstrates occipital hypometabolism. Parkinson\u2019s disease dementia often shows posterior cingulate hypometabolism (\u2018cingulate island sign\u2019) and less parietal involvement early on.","conceptual_foundation":"Alzheimer\u2019s disease (ICD-11 6D80) is characterized by progressive memory loss and cognitive decline due to amyloid-\u03b2 plaques and neurofibrillary tangles of tau in cortical regions. FDG-PET is used for differential diagnosis among dementias, with characteristic metabolic patterns aiding in subtype distinction.","pathophysiology":"AD features extracellular amyloid-\u03b2 deposition and intracellular paired helical filaments of hyperphosphorylated tau. Early synaptic dysfunction in the posterior cingulate, precuneus, and parietotemporal cortices leads to characteristic hypometabolism on FDG-PET.","clinical_manifestation":"Manifestations include insidious memory impairment, visuospatial dysfunction, language disturbance, and executive dysfunction. Early stage: episodic memory loss; middle: language and visuospatial deficits; late: global cognitive deterioration.","diagnostic_approach":"Use NIA-AA criteria: cognitive testing, MRI brain to rule out other causes, FDG-PET to support typical metabolic pattern. First-tier: MMSE/MoCA, MRI. Second-tier: FDG-PET or amyloid PET. Biomarkers: CSF A\u03b242/tau ratio.","management_principles":"Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are first line; memantine for moderate-severe AD. Lifestyle interventions include cognitive stimulation and physical exercise.","follow_up_guidelines":"Cognitive assessments every 6\u201312 months. Monitor for behavioral and psychological symptoms; adjust therapy accordingly.","clinical_pearls":"1) Parietotemporal hypometabolism on FDG-PET is characteristic of AD. 2) \u2018Cingulate island sign\u2019 favors DLB over AD. 3) ApoE \u03b54 allele increases AD risk. 4) CSF A\u03b242 reduction and tau elevation support AD. 5) Early memory impairment distinguishes AD from FTD.","references":"[1] Jack CR Jr et al. \u2018NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease.\u2019 Alzheimers Dement. 2018;14(4):535\u201362. DOI:10.1016/j.jalz.2018.02.018\n[2] Mosconi L et al. \u2018FDG-PET in differential diagnosis of dementia.\u2019 Eur J Nucl Med Mol Imaging. 2004;31(1):36\u201346. DOI:10.1007/s00259-003-1390-1"},"source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]